Bright Minds Biosciences
DRUG
34 hedge funds and large institutions have $188M invested in Bright Minds Biosciences in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
10% more funds holding
Funds holding: 31 → 34 (+3)
7% more capital invested
Capital invested by funds: $176M → $188M (+$12M)
6.43% less ownership
Funds ownership: 80.54% → 74.11% (-6.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$22.1M |
| 2 |
Millennium Management
New York
|
+$5.57M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.47M |
| 4 |
SCM
Sio Capital Management
New York
|
+$2.04M |
| 5 |
PA
Perceptive Advisors
New York
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.31M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$8.82M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.18M |
| 4 |
SFAM
Springhill Fund Asset Management
Hong Kong
|
-$2.18M |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$930K |
DRUG Hedge Fund Activity: Q1 2025 in Review
34 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q1 2025, worth a combined $188M — up 6.8% from $176M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DRUG positions and 7 closed out — a net gain of 3 holders — while 10 added to existing stakes and 8 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $22.1M. The largest seller was RA Capital Management, cutting an estimated $9.31M.
- 34 institutional investors held Bright Minds Biosciences (DRUG) as of Q1 2025, up from 31 in Q4 2024.
- Funds reported $188M of Bright Minds Biosciences stock for Q1 2025, up 6.8% quarter-over-quarter.
- 10 funds opened new Bright Minds Biosciences positions in Q1 2025 and 7 closed out, a net change of +3 holders.
- The largest Bright Minds Biosciences buyer in Q1 2025 was Janus Henderson Group, an estimated $22.1M added.
- The largest Bright Minds Biosciences seller in Q1 2025 was RA Capital Management, an estimated $9.31M sold.
Based on aggregated 13F filings for Q1 2025.